PACAP (6-38), human, ovine, rat TFA |
| Catalog No.GC36839 |
PACAP(6-38), 인간, 양, 쥐 TFA는 PACAP 유형 I 수용체, PACAP 유형 II 수용체 VIP1 및 PACAP 유형 II 수용체 VIP2에 대해 IC50이 각각 30, 600 및 40nM인 강력한 PACAP 수용체 길항제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 143748-18-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PACAP (6-38), human, ovine, rat TFA is a non-stimulatory competitive antagonist of pituitary adenylate cyclase-activating polypeptide (PACAP) with a Ki value of 2nM[1]. PACAP (6-38) acts on PACAP type I receptor, PACAP type II receptor VIP1 and PACAP type II receptor VIP2 with IC50 values of 30nM, 600nM and 40nM, respectively[2]. PACAP (6-38) can be used in neuroscience research (e.g., neuroprotection, pain regulation) and metabolic disease research (e.g., insulin secretion regulation)[3]. PACAP(6-38) can inhibit neuropeptide release from isolated tracheal sensory nerve endings[4].
In vitro, treatment of rat trigeminal ganglion cell cultures with PACAP (6-38) (1μM) for 6h induced transcriptome changes in the cells, resulting in a significant downregulation of NADH:ubiquinone oxidoreductase subunit B6 and a significant upregulation of transient receptor potential cation channel subfamily M member 8[5].
In vivo, PACAP (6-38) (0.3, 0.6, 3nM) injected intracerebroventricularly into SD mice blocked the reduction in solid food intake induced by cocaine and amphetamine regulated transcript (CARTp)[6]. PACAP (6-38) (300nM) injected intravesically into NGF-OE mice reduced baseline bladder pressure and pelvic sensitivity, but had no effect on bladder function in WT mice[7].
References:
[1] Fishbein V A, Coy D H, Hocart S J, et al. A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists[J]. Peptides, 1994, 15(1): 95-100.
[2] Gourlet P, Vandermeers A, Vandermeers-Piret M C, et al. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors[J]. European journal of pharmacology, 1995, 287(1): 7-11.
[3] Toth D, Szabo E, Tamas A, et al. Protective effects of PACAP in peripheral organs[J]. Frontiers in Endocrinology, 2020, 11: 377.
[4] Nemeth J, Reglödi D, Pozsgai G, et al. Effect of pituitary adenylate cyclase activating polypeptide-38 on sensory neuropeptide release and neurogenic inflammation in rats and mice[J]. Neuroscience, 2006, 143(1): 223-230.
[5] Takács-Lovász K, Kun J, Aczél T, et al. PACAP-38 induces transcriptomic changes in rat trigeminal ganglion cells related to neuroinflammation and altered mitochondrial function presumably via PAC1/VPAC2 receptor-independent mechanism[J]. International Journal of Molecular Sciences, 2022, 23(4): 2120.
[6] Burgos J R, Iresjö B M, Smedh U. Pituitary adenylate cyclase-activating polypeptide 6-38 blocks cocaine-and amphetamine-regulated transcript Peptide-induced hypophagia in rats[J]. PloS one, 2013, 8(8): e72347.
[7] Girard B M, Malley S E, Mathews M M, et al. Intravesical PAC1 receptor antagonist, PACAP (6–38), reduces urinary bladder frequency and pelvic sensitivity in NGF-OE mice[J]. Journal of Molecular Neuroscience, 2016, 59(2): 290-299.
| Cell experiment [1]: | |
Cell lines | Rat trigeminal ganglion cell cultures |
Preparation Method | Rat trigeminal ganglion cell cultures were incubated with 1µM PACAP-38 or PACAP (6-38). Six hours later RNA was isolated, next-generation RNA sequencing was performed and transcriptomic changes were analyzed to identify differentially expressed genes. |
Reaction Conditions | 1μM; 6h |
Applications | Transcriptomic changes induced by PACAP-38 and PACAP6-38 in cultured TG cells. Both PACAP-38 and PACAP (6-38) treatments caused significant downregulation of NADH: ubiquinone oxidoreductase subunit B6 and upregulation of transient receptor potential cation channel, subfamily M, member 8. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley rats |
Preparation Method | Eight rats with confirmed cannula placements were injected fourth i.c.v. on each testing day 20min prior to lights out and food access: 1.5µL of vehicle or PACAP (6-38), followed ten minutes later with 1.5µL of CARTp 55-102 (0.3nM: 1.5µg) or vehicle. The following PACAP 6-38 doses were used: 0.3nM, 0.6nM, 3nM. Food consumption was measured at 2, 5 and 22h. |
Dosage form | 0.3, 0.6, 3nM; i.c.v. |
Applications | PACAP (6-38) blocks Cocaine- and amphetamine-regulated transcript peptides (CARTp)-induced reductions in solid food intake. |
References: | |
| Cas No. | 143748-18-9 | SDF | |
| Formula | C184H301N56FO47S | M.Wt | 4138.76 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2416 mL | 1.2081 mL | 2.4162 mL |
| 5 mM | 0.0483 mL | 0.2416 mL | 0.4832 mL |
| 10 mM | 0.0242 mL | 0.1208 mL | 0.2416 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *